ALIM has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
ALIM has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Alimera Sciences's enterprise value is $239.45 Mil. Alimera Sciences's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 was $-1.12 Mil. Therefore, Alimera Sciences's EV-to-EBITDA for today is -214.75.
The historical rank and industry rank for Alimera Sciences's EV-to-EBITDA or its related term are showing as below:
During the past 13 years, the highest EV-to-EBITDA of Alimera Sciences was 614.32. The lowest was -245.44. And the median was -7.69.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
As of today (2024-05-13), Alimera Sciences's stock price is $3.555. Alimera Sciences's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was $-2.162. Therefore, Alimera Sciences's PE Ratio for today is At Loss.
The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.
The historical data trend for Alimera Sciences's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Alimera Sciences Annual Data | |||||||||||||||||||||
Trend | Dec14 | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | |||||||||||
EV-to-EBITDA | Get a 7-Day Free Trial | -36.08 | 28.94 | 20.17 | -8.22 | -250.61 |
Alimera Sciences Quarterly Data | ||||||||||||||||||||
Mar19 | Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | |
EV-to-EBITDA | Get a 7-Day Free Trial | -8.22 | -6.65 | -10.71 | -33.13 | -250.61 |
For the Drug Manufacturers - Specialty & Generic subindustry, Alimera Sciences's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Drug Manufacturers industry and Healthcare sector, Alimera Sciences's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Alimera Sciences's EV-to-EBITDA falls into.
Alimera Sciences's EV-to-EBITDA for today is calculated as:
EV-to-EBITDA | = | Enterprise Value (Today) | / | EBITDA (TTM) |
= | 239.451 | / | -1.115 | |
= | -214.75 |
Alimera Sciences's current Enterprise Value is $239.45 Mil.
Alimera Sciences's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.12 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Alimera Sciences (NAS:ALIM) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
Alimera Sciences's PE Ratio for today is calculated as:
PE Ratio | = | Share Price (Today) | / | Earnings per Share (Diluted) (TTM) |
= | 3.555 | / | -2.162 | |
= | At Loss |
Alimera Sciences's share price for today is $3.555.
Alimera Sciences's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-2.162.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.
Please read Which price ratio outperforms the enterprise multiple?
Thank you for viewing the detailed overview of Alimera Sciences's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.
Margaret Pax | director | 6310 TOWN SQUARE, SUITE 400, ALPHARETTA GA 30005 |
John Snisarenko | director | C/O ALIMERA SCIENCES, INC., 6120 WINDWARD PARKWAY, SUITE 290, ALPHARETTA GA 30005 |
Pizzo Peter J. Iii | director | 6120 WINDWARD PARKWAY, SUITE 290, ALPHARETTA GA 30005 |
Erin Parsons | director | 97 WILLISTON RD, BROOKLINE MA 02445 |
Caligan Partners Lp | 10 percent owner | 515 MADISON AVENUE, 8TH FLOOR, NEW YORK NY 10022 |
Ross D Demont | director | 51 PICKWICK ROAD, NEWTON MA 02465 |
C. Daniel Myers | other: Chairman Emeritus | 6120 WINDWARD PARKWAY, SUITE 290, ALPHARETTA GA 30005 |
David Edward Johnson | 10 percent owner | 590 MADISON AVENUE, NEW YORK NY 10022 |
Velan Capital Master Fund Lp | 10 percent owner | 1055B POWERS PLACE, ALPHARETTA GA 30009 |
Velan Capital Management Llc | 10 percent owner | 1055B POWERS PLACE, ALPHARETTA GA 30009 |
Velan Capital Holdings Llc | 10 percent owner | 1055B POWERS PLACE, ALPHARETTA GA 30009 |
Adam Morgan | director | 1055B POWERS PLACE, ALPHARETTA GA 30009 |
Velan Capital Investment Management Lp | 10 percent owner | 1055B POWERS PLACE, ALPHARETTA GA 30009 |
Velan Capital Spv I Llc | 10 percent owner | 1055B POWERS PLACE, ALPHARETTA GA 30009 |
Balaji Venkataraman | 10 percent owner | FIRST HORIZON PHARMACEUTICAL CORP, 660 HEMBREE PKWY STE 106, ROSWELL GA 30076 |
From GuruFocus
By Ds*** Ds*** • 08-31-2022
By Value_Insider Value_Insider • 11-29-2022
By sperokesalga sperokesalga • 02-22-2023
By GuruFocus Research • 08-23-2023
By Value_Insider Value_Insider • 12-08-2022
By sperokesalga sperokesalga • 05-24-2023
By Value_Insider Value_Insider • 11-01-2022
By sperokesalga sperokesalga • 03-27-2023
By sperokesalga sperokesalga • 05-18-2023
By Marketwired • 10-03-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.